PALI

Over the past six months, Palisade Bio received FDA and Health Canada clearances for its PALI-2108 Investigational New Drug (IND) and Clinical Trial Application (CTA) in September 2026, enabling Phase 2 trials for Crohn's disease and ulcerative colitis, which positively impacted the stock. In September 2026, the company announced positive topline Phase 1b clinical data for PALI-2108 in fibrostenotic Crohn's disease and moderate-to-severe UC, demonstrating favorable safety, tolerability, target engagement, and early signs of clinical activity. Q2 2026 financial results in August 2026 showed a wider net loss but highlighted the advancement of PALI-2108 into Phase 2 development, with earnings per share meeting analyst estimates. Analyst ratings improved, with Raymond James upgrading to a 'moderate buy' and initiating coverage with an 'Outperform' rating and a $6.00 price target in October 2026, while other analysts issued 'Buy' or 'Strong Buy' ratings with an average 1-year price objective of $9.83. The stock experienced volatility, trading between a 52-week high of $2.86 and a low of $1.32, with the share price around $1.44 - $1.46 in early October 2026, and was down 24.41% from October 2025 to October 2026. Insider buying activity was reported in July 2026, with $117,450 in buying and no selling over the last three months, indicating insider confidence.